(clarithromycin · DailyMed)
LANZOKIT
EACH HARD GELATIN CAPSULE CONTAINS: LANSOPRAZOLE DELAYED-RELEASE CAPSULES USP 30 MG TINIDAZOLE TABLETS 500 MG CLARITHROMYCIN TABLETS USP 250 MG
What it does
Clarithromycin is an antibiotic used to treat infections caused by bacteria.
Commonly used for: bacterial infections, chest infections (pneumonia), skin infections, ear infections (otitis media)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:24:38 · updated 2026-07-26 09:23:50
Drug Interactions
212Pharmacodynamic Warnings
Clarithromycin appears in TABLE 9: Drugs that prolong the QT interval
Severe (35)
Acalabrutinib - increases exposure
Clarithromycin is predicted to increase the exposure to acalabrutinib. Avoid.
Alprazolam - increases exposure
Clarithromycin moderately increases the exposure to benzodiazepines (alprazolam). Avoid.
Antihistamines,non-Sedating - increases exposure
Clarithromycin is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid.
Avapritinib - increases exposure
Clarithromycin is predicted to increase the exposure to avapritinib. Avoid.
Benzodiazepines - increases exposure
Clarithromycin moderately increases the exposure to benzodiazepines (alprazolam). Avoid.
Moderate (50)
Alfentanil - increases exposure
Clarithromycin is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose.
Aminophylline - increases exposure
Clarithromycin is predicted to increase the exposure to aminophylline. Adjust dose.
Amlodipine - increases exposure
Clarithromycin is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose.
Antiarrhythmics - increases exposure
Clarithromycin is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose.
Anticholinesterases, Centrally Acting - increases exposure
Clarithromycin is predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Monitor and adjust dose.
Unknown (127)
Abemaciclib - increases exposure
Clarithromycin is predicted to increase the exposure to abemaciclib. Avoid or adjust abemaciclib dose, p. 1056.
Afatinib - increases exposure
Macrolides are predicted to increase the exposure to afatinib.
Alitretinoin - increases exposure
Clarithromycin is predicted to increase the exposure to retinoids (alitretinoin). Adjust alitretinoin dose, p. 1382.
Almotriptan - increases exposure
Clarithromycin increases the exposure to triptans (almotriptan).
Alphablockers - increases exposure
Clarithromycin is predicted to increase the exposure to alpha blockers (doxazosin).
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About clarithromycin
Clarithromycin is an antibiotic used to treat infections caused by bacteria.
What it treats
- bacterial infections
- chest infections (pneumonia)
- skin infections
- ear infections (otitis media)
How it works
It works by stopping the growth of bacteria, helping your body to fight off the infection.
Who it's for
It is for adults and children with certain bacterial infections.
Drug class
Macrolides
Cautions
- • Be cautious if you are taking other medications that affect heart rhythm.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About gelatin
Gelatin is a substance often used in various food products and supplements. It is derived from animal collagen and is commonly used to help improve joint health and support digestion.
What it treats
- joint pain
- digestive health
- skin elasticity
How it works
Gelatin helps to provide structure to the body, supporting joints, skin, and digestive tract by providing essential proteins.
Who it's for
Gelatin is suitable for people looking to support their joint health, improve skin appearance, or enhance digestion.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About hard
Hard is a medicinal ingredient used to help with various health conditions.
How it works
Hard works by interacting with specific body systems to provide relief or treatment for certain conditions.
Who it's for
Hard is suitable for individuals experiencing the conditions it is meant to treat.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About lansoprazole
Lansoprazole is a medication that reduces stomach acid, helping to treat certain digestive issues.
What it treats
- acid reflux (gastroesophageal reflux disease)
- stomach ulcers (peptic ulcers)
- Zollinger-Ellison syndrome
How it works
It works by blocking the production of stomach acid, which helps heal and prevent damage to the stomach and esophagus.
Who it's for
It is for adults and children over the age of 1 who need relief from acid-related conditions.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About tinidazole
Tinidazole is an antibiotic used to treat infections caused by certain parasites and bacteria.
What it treats
- trichomoniasis (a sexually transmitted infection)
- giardiasis (a type of intestinal infection)
- amoebiasis (an infection caused by amoeba)
How it works
Tinidazole works by killing the harmful bacteria and parasites that cause infections.
Who it's for
Tinidazole is for adults and children who have specific types of infections.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Lansoprazole
BNF-referencedLansoprazole is a proton pump inhibitor (PPI) used primarily to treat gastric acid-related disorders such as gastro-oesophageal reflux disease, duodenal ulcers, and gastric ulcers. It functions by irreversibly inhibiting the H+,K+-ATPase enzyme in the gastric parietal cells, which is responsible for the final step in gastric acid secretion, thereby reducing gastric acidity and promoting healing of the gastrointestinal mucosa.
Indications
- Gastro-oesophageal reflux disease
- Duodenal ulcer
- Benign gastric ulcer
- NSAID-associated gastric or duodenal ulcer
- Zollinger-Ellison syndrome
Dosage
Adults: 30 mg once daily for 4 weeks for duodenal ulcers, 30 mg once daily for 8 weeks for gastric ulcers, and 15 mg once daily for maintenance treatment. For gastro-oesophageal reflux disease, the usual dose is 15 mg
Mechanism of action
Lansoprazole is a prodrug that becomes activated in an acidic environment. Once protonated, it forms stable disulfide bonds with cysteine residues on the H+,K+-ATPase enzyme in parietal cells. This covalent binding leads to prolonged inhibition of gastric acid secretion, affecting both basal and stimulated acid production regardless of the stimulus.
Pharmacodynamics
Lansoprazole decreases gastric acid secretion by specifically targeting the H+,K+-ATPase enzyme, which catalyzes the final step in gastric acid secretion. It effectively heals duodenal ulcers and alleviates symptoms associated with acid secretion, such as heartburn, while also reducing pepsin secretion. Its action is effective in both daytime and nocturnal acid secretion, making it useful in treating various acid-related disorders.
Pharmacokinetics
Lansoprazole is absorbed after oral administration, with peak plasma concentrations usually occurring within 1-2 hours. It is extensively metabolized in the liver primarily via cytochrome P450 enzymes, leading to various metabolites that are excreted in urine. The half-life of lansoprazole is approximately 1.5 hours, but its acid-suppressive effects last longer due to its mechanism of action. The presence of food can affect the absorption rate, so it is typically recommended to take lansoprazole before meals.
Contra-indications
- Hypersensitivity to lansoprazole or any of its excipients
- Concurrent use with rilpivirine-containing products
Adverse effects
- Headache
- Diarrhoea
- Nausea
- Abdominal pain
- Constipation
- Flatulence
- Dizziness
- Fatigue
- Skin rash
- Elevated liver enzymes
- Acute interstitial nephritis
- Clostridium difficile-associated diarrhoea
- Bone fractures
- Hypomagnesemia
Interactions
- Increased risk of gastrointestinal infections due to reduced gastric acidity
- Apalutamide may decrease exposure when used with lansoprazole
- May alter the absorption of drugs that require an acidic environment for optimal absorption
Precautions
- Use with caution in patients with hepatic impairment
- Monitor for signs of Clostridium difficile infection in patients with prolonged therapy
- Consider risk of hypomagnesemia and associated complications
Pregnancy
Manufacturer advises to avoid use during pregnancy due to lack of adequate human data.
Breast-feeding
Specialist sources indicate use with caution, as lansoprazole is likely to be present in human milk, but in small amounts probably too low to be harmful.
Storage
Store below 25°C in a dry place, protect from light.
Formulations
- Gastro-resistant capsules
- Oral suspension
- Gastro-resistant tablets
- Gastro-resistant granules
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: Tinidazole
BNF-referencedTinidazole is a synthetic antimicrobial drug with high efficacy against anaerobic bacteria and protozoa. It is primarily used to treat infections caused by Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica. Tinidazole has a longer duration of action compared to metronidazole, making it a suitable option for various infections.
Indications
- Intestinal amoebiasis
- Urogenital trichomoniasis
- Giardiasis
Dosage
Children: For children aged 1 month to 11 years, the dosage is 50–75 mg/kg once, with a maximum of 2 g per dose. For children aged 12 to 17 years, the dosage is 2 g for a single dose, which may be repeated once if necessary.
Adults: The usual adult dosage is 2 g taken orally as a single dose for urogenital trichomoniasis or giardiasis, and 1.5 g to 2 g once daily for 3 to 6 days for intestinal amoebiasis.
Mechanism of action
Tinidazole acts as a prodrug and antiprotozoal agent. Its nitro group is reduced in Trichomonas by a ferredoxin-mediated electron transport system, generating free nitro radicals that covalently bind to DNA, causing DNA damage and cell death. The exact mechanism of action against Giardia and Entamoeba species is not fully understood but is believed to be similar to that of Trichomonas.
Pharmacodynamics
Tinidazole demonstrates in vitro and clinical activity against Trichomonas vaginalis, Giardia duodenalis (also known as G. lamblia), and Entamoeba histolytica. It does not exhibit significant activity against most strains of vaginal lactobacilli, which are beneficial bacteria in the vaginal flora.
Pharmacokinetics
Tinidazole is well absorbed following oral administration, with peak plasma concentrations occurring within 0.5 to 3 hours. It is extensively distributed throughout body tissues and fluids. The drug undergoes hepatic metabolism and is eliminated primarily through the urine, with a half-life of approximately 12 to 14 hours. Clinical and laboratory monitoring is advised if treatment extends beyond 10 days.
Adverse effects
- Abdominal pain
- Decreased appetite
- Diarrhoea
- Headache
- Nausea
- Skin reactions
- Vertigo
- Vomiting
Precautions
- Clinical and laboratory monitoring is advised if treatment exceeds 10 days
Pregnancy
Manufacturer advises avoiding use in the first trimester.
Breast-feeding
Present in milk; the manufacturer advises avoiding breastfeeding during and for 3 days after stopping treatment.
Storage
Store below 25°C, protect from moisture.
Formulations
- Tinidazole 500 mg tablets
- Tinidazole oral suspension
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: Gelatin
BNF-referencedGelatin is a plasma substitute derived from protein obtained from plasma, serum, or normal placentas, with at least 95% of the protein being albumin. It is used to restore blood volume in patients with low blood volume conditions such as hypovolemic shock, burns, and during cardiopulmonary bypass procedures. Gelatin solutions can be isotonic, containing 3.5-5% protein, or concentrated, containing 15-25% protein.
Indications
- Low blood volume
- Hypovolemic shock
- Burns
- Cardiopulmonary bypass
Dosage
Children: Initially 10-20 mL per kilogram. Adjust according to the patient's condition and response, using 3.5-4% solution. Use under specialist supervision to mitigate the risk of fluid overload.
Adults: Dose according to requirements, typically administered intravenously. Consult product literature for specific dosing guidance.
Mechanism of action
Gelatin acts as a plasma expander by increasing the oncotic pressure in the vascular compartment, which helps to retain fluid within the bloodstream and restore circulating blood volume. This mechanism aids in maintaining blood pressure and improving tissue perfusion.
Pharmacodynamics
Gelatin solutions increase blood volume and improve hemodynamic stability in patients experiencing hypovolemic conditions. By drawing water into the vascular space, they help to counteract the effects of low blood volume, such as hypotension and compromised organ perfusion.
Pharmacokinetics
Gelatin is administered intravenously, and its effects can be observed relatively quickly. The half-life and the metabolic clearance depend on the formulation and concentration of the solution. Gelatin is gradually metabolized by macrophages and eliminated by the renal system. Close monitoring of fluid balance is essential, particularly in patients with cardiac or renal impairment.
Contra-indications
- Severe liver disease
- History of circulatory disease
- Severe cardiac disease
Adverse effects
- Fever
- Flushing
- Nausea
- Urticaria
- Rare or very rare shock
Interactions
- Calcium salts
Precautions
- Monitor cardiovascular and respiratory function
- Correct dehydration when administering
- Administer slowly to avoid rapid rise in blood pressure and cardiac failure
- Increased capillary permeability
Pregnancy
Consult product literature for specific guidance regarding use in pregnancy.
Breast-feeding
Consult product literature for specific guidance regarding use in breastfeeding.
Storage
Store at controlled room temperature, protect from light. Refer to product-specific storage instructions.
Formulations
- 5% solution for infusion
- 20% solution for infusion
- Concentrated solution (15-25% protein)
- Isotonic solution (3.5-5% protein)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: Clarithromycin
BNF-referencedClarithromycin is a macrolide antibiotic effective against a range of bacterial infections. It is primarily used in the treatment of community-acquired pneumonia, skin infections, and as a prophylactic measure for certain infections. Clarithromycin works by inhibiting bacterial protein synthesis, making it a crucial agent in combating gram-positive and some gram-negative bacteria.
Indications
- Bacterial infections
- Community-acquired pneumonia
- Skin infections
- Prophylaxis for certain infections
Dosage
Adults: 500 mg once daily for
Mechanism of action
Clarithromycin is metabolized to 14-OH clarithromycin, which is active. It penetrates bacterial cell walls and reversibly binds to domain V of the 23S ribosomal RNA of the 50S ribosomal subunit, blocking the translocation of aminoacyl-tRNA and inhibiting polypeptide synthesis. It may be bactericidal in high concentrations against susceptible organisms, particularly Streptococcus pyogenes, S. pneumoniae, Haemophilus influenzae, and Chlamydia trachomatis. Additionally, clarithromycin inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein.
Pharmacodynamics
Clarithromycin exhibits a broad spectrum of activity against numerous gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. It also shows activity against gram-negative bacteria such as Haemophilus influenzae and Moraxella catarrhalis, as well as against various anaerobic bacteria, mycobacteria, and other organisms like Mycoplasma, Ureaplasma, and Chlamydia. While typically bacteriostatic, it can sometimes demonstrate bactericidal properties depending on the concentration and the organism.
Pharmacokinetics
Clarithromycin is well absorbed after oral administration, with its bioavailability enhanced by food. It is extensively metabolized in the liver, primarily via CYP3A4, leading to active metabolites. The drug has a half-life of approximately 3 to 4 hours, but its active metabolite, 14-OH clarithromycin, has a longer half-life, contributing to its prolonged activity. Renal impairment can significantly affect its clearance, necessitating dosage adjustments in patients with reduced renal function.
Adverse effects
- Nausea
- Diarrhea
- Abdominal pain
- Dysgeusia
- Headache
- Rash
- Liver enzyme elevations
- QT prolongation
Interactions
- Clarithromycin + acalabrutinib: Severe (increases exposure)
- Clarithromycin + antiarrhythmics: Severe (increases exposure)
- Clarithromycin + dronedarone: Severe (increases exposure)
- Clarithromycin + non-sedating antihistamines: Severe (increases exposure)
- Clarithromycin + mizolastine: Severe (increases exposure)
- Clarithromycin + lurasidone: Severe (increases exposure)
- Clarithromycin + quetiapine: Severe (increases exposure)
- Clarithromycin + avapritinib: Severe (increases exposure)
- Clarithromycin + benzodiazepines: Severe (increases exposure)
- Clarithromycin + alprazolam: Severe (increases exposure)
Precautions
- Caution in hepatic impairment
- Use with caution in renal impairment
- Monitor for signs of QT prolongation
- Consider alternative therapy in patients with history of arrhythmias
- Use with caution in patients with myasthenia gravis due to potential exacerbation
Pregnancy
Manufacturers advise use only if adequate alternatives are not available.
Breast-feeding
Present in milk; use only if no suitable alternatives.
Storage
Store in a cool, dry place away from light. Keep out of reach of children.
Formulations
- Oral suspension 200 mg/5 mL
- Capsules 250 mg
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: hard
Hard, commonly referred to in various contexts, can refer to a range of substances or drugs depending on the specific context. In pharmacology, it is crucial to specify the drug in question for accurate information. Generally, the term may allude to substances that exhibit a strong, potent effect on the body, leading to significant pharmacological actions. The effects can vary widely based on the specific compound in question, its classification, and its intended medical use.
Dosage
Children: Refer to specific pediatric dosing guidelines based on the identified drug, as 'hard' does not provide sufficient information.
Adults: Refer to specific drug information for dosing guidelines, as 'hard' does not specify a particular medication.
Mechanism of action
The mechanism of action for drugs termed 'hard' must be specified for accurate information, as this phrase does not designate a specific compound. Mechanisms may involve receptor interaction, enzyme inhibition, or modulation of biochemical pathways, depending on the drug in question. For example, opioid analgesics work primarily by binding to mu-opioid receptors in the central nervous system, leading to analgesic effects.
Pharmacodynamics
Pharmacodynamics refers to the effects of a drug on the body and its mechanisms of action. The pharmacodynamics of any drug classified as 'hard' would depend on its specific pharmacological profile, including its efficacy, potency, and the nature of its therapeutic effects. For instance, in the case of opioids, pharmacodynamic effects include pain relief, sedation, and potential respiratory depression.
Pharmacokinetics
Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. The pharmacokinetics of a substance termed 'hard' would vary significantly based on the specific drug. For many medications, absorption may occur via oral or parenteral routes, distribution may involve binding to plasma proteins, metabolism may occur in the liver, and excretion is typically renal. Each of these parameters is critical for understanding the drug's action and potential side effects.
Pregnancy
Consult a healthcare professional before use, as safety has not been established.
Breast-feeding
Consult a healthcare professional before use, as safety has not been established.
Storage
Store in a cool, dry place, away from direct sunlight.
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Clarithromycin
PubChem CID 84029Molecular formula: C38H69NO13
Mechanism of action
Clarithromycin is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. Like other macrolides, it then penetrates bacteria cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide synthesis. Clarithromycin also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump. Clarithromycin usually is bacteriostatic, although it may be bactericidal in high concentrations or against highly susceptible organisms. Bactericidal activity has been observed against Streptococcus pyogenes, S. pneumoniae, Haemophilus influenzae, and Chlamydia trachomatis. Clarithromycin inhibits protein synthesis in susceptible organisms by penetrating the cell wall and binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. The site of action of clarithromycin appears to be the same as that of erythromycin, clindamycin, lincomycin, and chloramphenicol.
Pharmacodynamics
Clarithromycin is a macrolide antibiotic whose spectrum of activity includes many gram-positive (<i>Staphylococcus aureus, S. pneumoniae, and S. pyogenes</i>) and gram-negative aerobic bacteria (<i>Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis</i>), many anaerobic bacteria, some mycobacteria, and some other organisms including <i>Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma</i>, and <i>Borrelia</i>. Other aerobic bacteria that clarithromycin has activity against include <i>C. pneumoniae and M. pneumoniae</i>. Clarithromycin has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Clarithromycin is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.
Biological pathways
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
Molecular reference: Lansoprazole
PubChem CID 3883Molecular formula: C16H14F3N3O2S
Mechanism of action
As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides. PPI's in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets. Lansoprazole is a selective and irreversible proton pump inhibitor. In the acidic environment of the gastric parietal cell, lansoprazole is converted to active sulphenamide derivatives that bind to the sulfhydryl group of (H+, K+)-adenosine triphosphatase ((H+,K+)-ATPase), also known as the proton pump (H+,K+)-ATPase catalyzes the final step in the gastric acid secretion pathway. Lansoprazole's inhibition of (H+,K+)-ATPase results in inhibition of both centrally and peripherally mediated gastric acid secretion. The inhibitory effect is dose-related. Lansoprazole inhibits both basal and stimulated gastric acid secretion regardless of the stimulus.
Pharmacodynamics
Lansoprazole decreases gastric acid secretion by targeting H+,K+-ATPase, which is the enzyme that catalyzes the final step in the acid secretion pathway in parietal cells. Conveniently, lansoprazole administered any time of day is able to inhibit both daytime and nocturnal acid secretion. The result is that lansoprazole is effective at healing duodenal ulcers, reduces ulcer-related pain, and offers relief from symptoms of heartburn Lansoprazole also reduces pepsin secretion, making it a useful treatment option for hypersecretory conditions such as Zollinger-Ellison syndrome.
Biological pathways
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
Molecular reference: Tinidazole
PubChem CID 5479Molecular formula: C8H13N3O4S
Mechanism of action
Tinidazole is a prodrug and antiprotozoal agent. The nitro group of tinidazole is reduced in <i>Trichomonas</i> by a ferredoxin-mediated electron transport system. The free nitro radical generated as a result of this reduction is believed to be responsible for the antiprotozoal activity. It is suggested that the toxic free radicals covalently bind to DNA, causing DNA damage and leading to cell death. The mechanism by which tinidazole exhibits activity against <i>Giardia</i> and <i>Entamoeba</i> species is not known, though it is probably similar. The nitro group of tinidazole is reduced by cell extracts of Trichomonas. As a result of this reduction a free nitro radical is generated which may be responsible for the antiprotozoal activity. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.
Pharmacodynamics
Tinidazole is a synthetic antiprotozoal agent. Tinidazole demonstrates activity both in vitro and in clinical infections against the following protozoa: <i>Trichomonas vaginalis</i>, <i>Giardia duodenalis</i> (also termed <i>G. lamblia</i>), and <i>Entamoeba histolytica</i>. Tinidazole does not appear to have activity against most strains of vaginal lactobacilli.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- ACEM-500 500MG TABLET
- ASRITHO 500MG TABLET
- AZICLAR-500 500MG TABLET
- CIPROBIOTIC-TN COMBINATION PRODUCT TABLET
- CITI COMBINATION PRODUCT TABLET
- CITIZOL COMBINATION PRODUCT TABLET
- AJ WELLNESS VITALWOMAN 45+ CAPSULES · Renown Pharmaceuticals
- CIPROLEX /TZ TABLETS · Dupen Laboratories
- CIPROMOON TZ TABLET · Mccoy Pharma
- CIPROTOB TZ TABLETS · Entrance Pharmaceuticals
- CIPROTRUST-TZ TABLETS (Each film-coated tablet contains Ciprofloxacin/Tinidazole 500mg/600mg) · Centurion Laboratories
- CLANZAS SOFT CAPSULES · Aura Lifecare